MEFENAMIC Drug Patent Profile
✉ Email this page to a colleague
When do Mefenamic patents expire, and when can generic versions of Mefenamic launch?
Mefenamic is a drug marketed by Ajenat Pharms, Chartwell Rx, Lupin Ltd, Micro Labs, and Mpp Pharma. and is included in five NDAs.
The generic ingredient in MEFENAMIC is mefenamic acid. There are thirteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the mefenamic acid profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Mefenamic
A generic version of MEFENAMIC was approved as mefenamic acid by MICRO LABS on November 19th, 2010.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for MEFENAMIC?
- What are the global sales for MEFENAMIC?
- What is Average Wholesale Price for MEFENAMIC?
Summary for MEFENAMIC
| US Patents: | 0 |
| Applicants: | 5 |
| NDAs: | 5 |
| DailyMed Link: | MEFENAMIC at DailyMed |
US Patents and Regulatory Information for MEFENAMIC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ajenat Pharms | MEFENAMIC ACID | mefenamic acid | CAPSULE;ORAL | 091608-001 | Jun 2, 2014 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Micro Labs | MEFENAMIC ACID | mefenamic acid | CAPSULE;ORAL | 090562-001 | Nov 19, 2010 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Chartwell Rx | MEFENAMIC ACID | mefenamic acid | CAPSULE;ORAL | 209209-001 | Sep 18, 2020 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
